Medulloblastoma (MB) is a highly aggressive pediatric tumor of the cerebellum. Hyperactivation of the Hedgehog (HH) pathway is observed in about 30% of all MB diagnoses, thereby bringing out its pharmacological blockade as a promising therapeutic strategy for the clinical management of this malignancy. Two main classes of HH inhibitors have been developed: upstream antagonists of Smoothened (SMO) receptor and downstream inhibitors of GLI transcription factors. Unfortunately, the poor pharmacological properties of many of these molecules have limited their investigation in clinical trials for MB. In this minireview, we focus on the drug delivery systems engineered for SMO and GLI inhibitors as a valuable approach to improve their bioavailability and efficiency to cross the blood–brain barrier (BBB), one of the main challenges in the treatment of MB.

Drug delivery systems for hedgehog inhibitors in the treatment of SHH-medulloblastoma / Caimano, M.; Lospinoso Severini, L.; Loricchio, E.; Infante, P.; Di Marcotullio, L.. - In: FRONTIERS IN CHEMISTRY. - ISSN 2296-2646. - 9:(2021). [10.3389/fchem.2021.688108]

Drug delivery systems for hedgehog inhibitors in the treatment of SHH-medulloblastoma

Caimano M.;Lospinoso Severini L.;Loricchio E.;Infante P.
;
Di Marcotullio L.
2021

Abstract

Medulloblastoma (MB) is a highly aggressive pediatric tumor of the cerebellum. Hyperactivation of the Hedgehog (HH) pathway is observed in about 30% of all MB diagnoses, thereby bringing out its pharmacological blockade as a promising therapeutic strategy for the clinical management of this malignancy. Two main classes of HH inhibitors have been developed: upstream antagonists of Smoothened (SMO) receptor and downstream inhibitors of GLI transcription factors. Unfortunately, the poor pharmacological properties of many of these molecules have limited their investigation in clinical trials for MB. In this minireview, we focus on the drug delivery systems engineered for SMO and GLI inhibitors as a valuable approach to improve their bioavailability and efficiency to cross the blood–brain barrier (BBB), one of the main challenges in the treatment of MB.
2021
blood–brain barrier; drug delivery; GLI inhibitors; hedgehog signaling; medulloblastoma; nanoparticles; SMO antagonists
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Drug delivery systems for hedgehog inhibitors in the treatment of SHH-medulloblastoma / Caimano, M.; Lospinoso Severini, L.; Loricchio, E.; Infante, P.; Di Marcotullio, L.. - In: FRONTIERS IN CHEMISTRY. - ISSN 2296-2646. - 9:(2021). [10.3389/fchem.2021.688108]
File allegati a questo prodotto
File Dimensione Formato  
Caimano_Drug-delivery-system_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 962.16 kB
Formato Adobe PDF
962.16 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1613665
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 11
social impact